Anti-Infective Agents Market By Drug Class (Antibiotics, Antivirals, Antifungals, Antiprotozoals, Anthelmintics, Others), By Application (Skin Infections, Respiratory Tract Infections, Gastrointestinal Infections, Central Nervous System Infections, Others), By Route of Administration (Oral, Topical, Injectable, Inhalation), By End-User (Hospitals and Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs),Research and Diagnostic Laboratories), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Anti-Infective Agents Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising global incidence of infectious diseases driving demand for treatments.

3.2.2. Growing awareness of drug-resistant infections boosts the need for new anti-infectives.

3.2.3. Expanding healthcare infrastructure and access in developing regions.

3.3. Key industry pitfalls & challenges

3.3.1. High research, development, and approval costs limit the growth of anti-infectives.

3.3.2. Increasing antibiotic resistance limiting treatment effect.

3.3.3. Stringent regulatory approvals delaying drug market entry.

3.4. Market Opportunities

3.4.1. Advancements in personalized medicine offer targeted treatments for infectious diseases.

3.4.2. Expanding healthcare infrastructure in emerging markets increases demand for anti-infective treatments.

3.4.3. Development of biologics and immunotherapies for infections.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Anti-Infective Agents Market, Drug Class Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Drug Class, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Antibiotics

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Antivirals

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Antifungals

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Antiprotozoals

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Anthelmintics

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.7. Others

4.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Anti-Infective Agents Market, Application Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Application, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Skin Infections

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Respiratory Tract Infections

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Gastrointestinal Infections

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Central Nervous System Infections

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Others

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Anti-Infective Agents Market, Route of Administration Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Oral

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Topical

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Injectable

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Inhalation

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Anti-Infective Agents Market, End-User Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-User, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Hospitals and Clinics

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Homecare Settings

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Ambulatory Surgical Centers (ASCs)

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Research and Diagnostic Laboratories

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Anti-Infective Agents Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

8.2.2. North America Market Revenue, By Drug Class, 2025-2035

8.2.3. North America Market Revenue, By Application, 2025-2035

8.2.4. North America Market Revenue, By Route of Administration, 2025-2035

8.2.5. North America Market Revenue, By End-User, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Drug Class, 2025-2035

8.2.6.2. U.S. Market Revenue, By Application, 2025-2035

8.2.6.3. U.S. Market Revenue, By Route of Administration, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-User, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Drug Class, 2025-2035

8.2.7.2. Canada Market Revenue, By Application, 2025-2035

8.2.7.3. Canada Market Revenue, By Route of Administration, 2025-2035

8.2.7.4. Canada Market Revenue, By End-User, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

8.3.2. Europe Market Revenue, By Drug Class, 2025-2035

8.3.3. Europe Market Revenue, By Application, 2025-2035

8.3.4. Europe Market Revenue, By Route of Administration, 2025-2035

8.3.5. Europe Market Revenue, By End-User, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Drug Class, 2025-2035

8.3.6.2. Germany Market Revenue, By Application, 2025-2035

8.3.6.3. Germany Market Revenue, By Route of Administration, 2025-2035

8.3.6.4. Germany Market Revenue, By End-User, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Drug Class, 2025-2035

8.3.7.2. France Market Revenue, By Application, 2025-2035

8.3.7.3. France Market Revenue, By Route of Administration, 2025-2035

8.3.7.4. France Market Revenue, By End-User, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Drug Class, 2025-2035

8.3.8.2. U.K. Market Revenue, By Application, 2025-2035

8.3.8.3. U.K. Market Revenue, By Route of Administration, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-User, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Drug Class, 2025-2035

8.3.9.2. Italy Market Revenue, By Application, 2025-2035

8.3.9.3. Italy Market Revenue, By Route of Administration, 2025-2035

8.3.9.4. Italy Market Revenue, By End-User, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Drug Class, 2025-2035

8.3.10.2. Spain Market Revenue, By Application, 2025-2035

8.3.10.3. Spain Market Revenue, By Route of Administration, 2025-2035

8.3.10.4. Spain Market Revenue, By End-User, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Drug Class, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Application, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-User, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

8.4.2. Asia Pacific Market Revenue, By Drug Class, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Application, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-User, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Drug Class, 2025-2035

8.4.6.2. China Market Revenue, By Application, 2025-2035

8.4.6.3. China Market Revenue, By Route of Administration, 2025-2035

8.4.6.4. China Market Revenue, By End-User, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Drug Class, 2025-2035

8.4.7.2. Japan Market Revenue, By Application, 2025-2035

8.4.7.3. Japan Market Revenue, By Route of Administration, 2025-2035

8.4.7.4. Japan Market Revenue, By End-User, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Drug Class, 2025-2035

8.4.8.2. India Market Revenue, By Application, 2025-2035

8.4.8.3. India Market Revenue, By Route of Administration, 2025-2035

8.4.8.4. India Market Revenue, By End-User, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Drug Class, 2025-2035

8.4.9.2. Australia Market Revenue, By Application, 2025-2035

8.4.9.3. Australia Market Revenue, By Route of Administration, 2025-2035

8.4.9.4. Australia Market Revenue, By End-User, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Drug Class, 2025-2035

8.4.10.2. South Korea Market Revenue, By Application, 2025-2035

8.4.10.3. South Korea Market Revenue, By Route of Administration, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-User, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Drug Class, 2025-2035

8.4.11.2. Singapore Market Revenue, By Application, 2025-2035

8.4.11.3. Singapore Market Revenue, By Route of Administration, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-User, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Drug Class, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Application, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-User, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

8.5.2. Latin America Market Revenue, By Drug Class, 2025-2035

8.5.3. Latin America Market Revenue, By Application, 2025-2035

8.5.4. Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.5. Latin America Market Revenue, By End-User, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Drug Class, 2025-2035

8.5.6.2. Brazil Market Revenue, By Application, 2025-2035

8.5.6.3. Brazil Market Revenue, By Route of Administration, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-User, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Drug Class, 2025-2035

8.5.7.2. Argentina Market Revenue, By Application, 2025-2035

8.5.7.3. Argentina Market Revenue, By Route of Administration, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-User, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Drug Class, 2025-2035

8.5.8.2. Mexico Market Revenue, By Application, 2025-2035

8.5.8.3. Mexico Market Revenue, By Route of Administration, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-User, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Drug Class, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Application, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-User, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

8.6.2. MEA Market Revenue, By Drug Class, 2025-2035

8.6.3. MEA Market Revenue, By Application, 2025-2035

8.6.4. MEA Market Revenue, By Route of Administration, 2025-2035

8.6.5. MEA Market Revenue, By End-User, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Drug Class, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Application, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Route of Administration, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-User, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Drug Class, 2025-2035

8.6.7.2. South Africa Market Revenue, By Application, 2025-2035

8.6.7.3. South Africa Market Revenue, By Route of Administration, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-User, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Drug Class, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Application, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-User, 2025-2035

9. Company Profile

9.1. Pfizer Inc.

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Merck & Co., Inc.

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. GlaxoSmithKline (GSK)

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Johnson & Johnson

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Novartis AG

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Sanofi S.A.

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Spexis AG

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. AstraZeneca PLC

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Eli Lilly and Company

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Bristol-Myers Squibb

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Teva Pharmaceutical Industries Ltd.

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. F. Hoffmann-La Roche Ltd.

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Mylan N.V.

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Allergan

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Basilea Pharmaceutical

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis

9.16. Globe Biotech Ltd.

9.16.1. Business Overview

9.16.2. Financial Performance

9.16.3. Product/Service Offerings

9.16.4. Strategies & recent developments

9.16.5. SWOT Analysis

9.17. Cubist Pharmaceuticals

9.17.1. Business Overview

9.17.2. Financial Performance

9.17.3. Product/Service Offerings

9.17.4. Strategies & recent developments

9.17.5. SWOT Analysis